Detalles de la búsqueda
1.
A proof-of-concept randomized crossover clinical trial of a first-in-class vasopressin 1a receptor antagonist for PTSD: Design, methods, and recruitment.
Contemp Clin Trials Commun
; 33: 101116, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-37008794
2.
The Vasopressin 1a Receptor Antagonist SRX246 Reduces Aggressive Behavior in Huntington's Disease.
J Pers Med
; 12(10)2022 Sep 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-36294700
3.
The novel vasopressin receptor (V1aR) antagonist SRX246 reduces anxiety in an experimental model in humans: a randomized proof-of-concept study.
Psychopharmacology (Berl)
; 238(9): 2393-2403, 2021 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-33970290
4.
Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington's Disease Patients-A Randomized Phase 2 Clinical Trial.
J Clin Med
; 9(11)2020 Nov 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-33207828
5.
HIV-1 Tat B-cell epitope vaccination was ineffectual in preventing viral rebound after ART cessation: HIV rebound with current ART appears to be due to infection with new endogenous founder virus and not to resurgence of pre-existing Tat-dependent viremia.
Hum Vaccin Immunother
; 8(10): 1425-30, 2012 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-23095869
Resultados
1 -
5
de 5
1
Próxima >
>>